Literature DB >> 11027561

Interferon-gamma directly inhibits TRANCE-induced osteoclastogenesis.

S W Fox1, T J Chambers.   

Abstract

The immune system has profound effects on bone remodeling. IFN-gamma, a major product of immune cells, potently inhibits bone resorption, but its mechanism of action is unknown. We found in cultures of stroma-free mononuclear precursors that IFN-gamma strongly suppresses TRANCE/RANKL-induced osteoclast formation in a dose-dependent manner. This direct effect on osteoclast progenitors was not due to stimulation of NO production by IFN-gamma, as the NOS inhibitors 1400W and L-NAME were unable to reverse the suppression. However, TGFbeta(1), which has opposing actions to IFN-gamma on diverse cellular functions, was able to antagonize the effect of IFN-gamma. This suggests that IFN-gamma prevents osteoclast formation by actively directing the differentiation of osteoclastic progenitors toward an alternative cytocidal lineage to the osteoclast. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11027561     DOI: 10.1006/bbrc.2000.3577

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  17 in total

1.  Molecular mechanisms of the biphasic effects of interferon-γ on osteoclastogenesis.

Authors:  Jing Cheng; Jianzhong Liu; Zhenqi Shi; Joel Jules; Duorong Xu; Shaokai Luo; Shi Wei; Xu Feng
Journal:  J Interferon Cytokine Res       Date:  2011-12-05       Impact factor: 2.607

Review 2.  Osteoclasts: New Insights.

Authors:  Xu Feng; Steven L Teitelbaum
Journal:  Bone Res       Date:  2013-03-29       Impact factor: 13.567

3.  Gamma interferon positively modulates Actinobacillus actinomycetemcomitans-specific RANKL+ CD4+ Th-cell-mediated alveolar bone destruction in vivo.

Authors:  Yen-Tung A Teng; Deeqa Mahamed; Bhagirath Singh
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

4.  Functional characterization of human osteoclast inhibitory peptide-1 (OIP-1/hSca) gene promoter.

Authors:  Shanmugarajan Srinivasan; Masahiro Ito; Hiroshi Kajiya; L Lyndon Key; Theresa L Johnson-Pais; Sakamuri V Reddy
Journal:  Gene       Date:  2005-12-27       Impact factor: 3.688

5.  IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation.

Authors:  Yuhao Gao; Francesco Grassi; Michaela Robbie Ryan; Masakazu Terauchi; Karen Page; Xiaoying Yang; M Neale Weitzmann; Roberto Pacifici
Journal:  J Clin Invest       Date:  2006-12-14       Impact factor: 14.808

6.  Interleukin-27 suppresses osteoclastogenesis via induction of interferon-γ.

Authors:  Jin-Sil Park; Young Ok Jung; Hye-Joa Oh; Seong Jeong Park; Yu-Jung Heo; Chang-Min Kang; Seung-Ki Kwok; Ji Hyeon Ju; Kyung Su Park; Mi-La Cho; Young-Chul Sung; Sung-Hwan Park; Ho-Youn Kim
Journal:  Immunology       Date:  2012-12       Impact factor: 7.397

Review 7.  The immune system and bone.

Authors:  Roberto Pacifici
Journal:  Arch Biochem Biophys       Date:  2010-06-17       Impact factor: 4.013

8.  Osteoclast-Primed Foxp3+ CD8 T Cells Induce T-bet, Eomesodermin, and IFN-γ To Regulate Bone Resorption.

Authors:  Elena V Shashkova; Jahnavi Trivedi; Anna B Cline-Smith; Chloe Ferris; Zachary S Buchwald; Jesse Gibbs; Deborah Novack; Rajeev Aurora
Journal:  J Immunol       Date:  2016-06-20       Impact factor: 5.422

9.  Interferon-gamma targets cancer cells and osteoclasts to prevent tumor-associated bone loss and bone metastases.

Authors:  Zhiqiang Xu; Michelle A Hurchla; Hongju Deng; Ozge Uluçkan; Fang Bu; Andrew Berdy; Mark C Eagleton; Emanuela A Heller; Desiree H Floyd; Wessel P Dirksen; Sherry Shu; Yuetsu Tanaka; Soledad A Fernandez; Thomas J Rosol; Katherine N Weilbaecher
Journal:  J Biol Chem       Date:  2008-12-05       Impact factor: 5.157

10.  Alpha1beta1 integrin and interleukin-7 receptor up-regulate the expression of RANKL in human T cells and enhance their osteoclastogenic function.

Authors:  Steve Gendron; Marc Boisvert; Nizar Chetoui; Fawzi Aoudjit
Journal:  Immunology       Date:  2008-05-13       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.